Guides
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Opthea.
RELATED STOCKHEAD STORIES
Experts
Scopo’s health powerplays: Get ready for the pullback
Health & Biotech
Large caps deny they’re being outgunned by smaller peers in health R&D
Health & Biotech
Check up: Sometimes no news is good news
Health & Biotech
What’s Opthea eyeing now that it has two successful trials under its belt?
Health & Biotech
Opthea’s done it again: Its drug passed its DME clinical trial
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Clock’s Ticking: In 24 hours we’ll know if Opthea’s DME clinical trial was successful
Experts
Scopo’s health powerplays: You’re all going to the pot, literally
Health & Biotech
We’re still here: investors keen on health despite market shun
Health & Biotech
TGA says no to 13 eye drugs, elderly still waiting for something that works
Experts
